Richard van Logtenstein

A largely random AAV integration profile after LPLD gene therapy

Christine Kaeppel, Stuart G. Beattie, Raffaele Fronza et al. · Nature Medicine · 2013 · 191 citations · Full text

Gene Therapies, Lpld Gene Therapy, Cell Therapy +7

Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery

Anna Majowicz, Piotr Maczuga, Karin L. Kwikkers et al. · The Journal of Gene Medicine · 2013 · 64 citations

In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs.

Florie Borel, Richard van Logtenstein, Annemart Koornneef et al. · PubMed · 2011 · 47 citations · Full text

Engineering, Abc Transporters, Immunology +23

Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice

Annemart Koornneef, Piotr Maczuga, Richard van Logtenstein et al. · Molecular Therapy · 2011 · 31 citations · Full text

Embedding siRNA sequences targeting Apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy

Piotr Maczuga, Jacek Lubelski, Richard van Logtenstein et al. · Molecular Therapy · 2012 · 28 citations · Full text